Detalhe da pesquisa
1.
Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry.
Cytometry A
; 85(12): 1020-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25155056
2.
microRNAs as pharmacological targets in cancer.
Pharmacol Res
; 75: 3-14, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23537752
3.
Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro.
Cancers (Basel)
; 13(19)2021 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638328
4.
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.
Cancer Cell
; 36(5): 512-527.e9, 2019 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31631027
5.
Targeting of epigenetic regulators in neuroblastoma.
Exp Mol Med
; 50(4): 1-12, 2018 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29700278
6.
Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions.
Oncotarget
; 8(16): 26298-26311, 2017 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28412746
7.
miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer.
Cell Death Dis
; 8(10): e3141, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29072692
8.
MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.
Oncotarget
; 7(8): 9271-87, 2016 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-26824183
9.
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Cancer Res
; 73(20): 6264-76, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23950209